Recent Finacing
Recent Raise
SERDA Therapeutics, a Smith and Nephew and NLC JV, develops SN514 enzymatic debridement for burns and ulcers; completed IND, in Phase I planning Phase IIa with US Army support.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor